Outcomes at 7 years post‐transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in<scp>BENEFIT</scp>and<scp>BENEFIT</scp>‐<scp>EXT</scp>Sander Florman, Christian P. Larsen, Antoine Dürrbach et al.|Clinical Transplantation|2018Cited by 9
mTOR Inhibition Impairs the Activation and Function of Belatacept-Resistant CD4+CD57+ T Cells In Vivo and In VitroFlorence Herr, Antoine Dürrbach|Pharmaceutics|2023Cited by 3